PhRMA goes on the of­fen­sive, at­tack­ing the WHO and putting the EU, UK, Aus­tralia and oth­ers on no­tice

Each year, in­dus­try groups like PhRMA of­fer their views on which coun­tries around the globe might be harm­ing bio­phar­ma in­no­va­tion as a re­sult of their in­tel­lec­tu­al prop­er­ty pro­tec­tions or lack there­of, which can con­tribute to a re­port pro­duced by the White House’s trade rep­re­sen­ta­tive on the glob­al state of IP.

This year’s 273 pages worth of com­ments from PhRMA not on­ly take is­sue with the Biden ad­min­is­tra­tion’s pledge to sup­port an IP waiv­er for Covid-19 vac­cines at the WTO, but al­so raise con­cerns about the WHO and oth­er coun­tries on the pri­or­i­ty watch list, like Cana­da, and the in­dus­try group has re­quest­ed that the US trade rep­re­sen­ta­tive add Aus­tralia, Tai­wan, the EU, UK, Egypt and Is­rael to its “watch list.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.